IDO1 and neoplasm: Because two patients died of non-tumor-related causes and one patient had tumor rupture during surgery, we analyzed the prognostic relevance of the changes of tumor IDO1 expression and CD8+TILs status after neoadjuvant therapy in 82 patients and the median follow-up time was 33.5 months (range, 5.3-76.5).